Course of intrahospital coronavirus infection (COVID-19) against the background of preventive and curative administration of peptide immunotropic drugs as part of complex therapy


Due to the lack of COVID-19 specific preventive measures with a prophylactic and therapeutic (as part of complex therapy) purpose, various drugs were used as humanitarian aid from manufacturing companies to prevent influenza and SARS in St. Petersburg hospitals.

The study of Russian Scientific Research Institute of Traumatology and Orthopedics named after R.R. Vreden patient treatment shows the possibility of using drugs containing a synthetic regulatory thymus peptide (L-glutamine-L-tryptophan-thymogen) as an active ingredient in a patient with an in-hospital coronavirus infection. This compound has a number of extra- and intracellular immunotropic effects of key importance in the pathogenesis of respiratory viral infections, including coronavirus etiology. The components have an indirect antiviral effect against acute respiratory viral infections, comprising COVID-19.

This led to the use of drugs containing thymogen for the prevention and treatment of COVID-19. The use of immunotropic agents promoted the rapid involution in the patient of clinical, laboratory and instrumental (radiological) signs of the disease and its uncomplicated course both in the primary infection and the development of superinfection cases. The study has shown that the use for the prevention and treatment (as part of complex therapy) of drugs with immunomodulatory activity, as well as those capable of affecting various links in the pathogenesis of pulmonary lesions in coronavirus infection, seems to be highly relevant and justified.

About the authors

Sergey V. Petlenko

MBSPC Cytomed, Saint Petersburg, Russia; Toxicology, Federal Medical-Biological Agency, Saint Petersburg, Russia

Author for correspondence.
Scopus Author ID: 407034

Russian Federation, 194356, Россия, Санкт-Петербург, Орлово-Денисовский проспект, дом 14 строение 1; 192019, Россия, Санкт-Петербург, ул.Бехтерева, д.1

Doctor  of  Medicine  (MD),  Head of Clinical Research Department, Leading Researcher

Vyacheslav S. Smirnov

MBSPC Cytomed, Saint Petersburg, Russia; Saint-Petersburg Pasteur Institute, Saint Petersburg, Russia

SPIN-code: 6276-2918
Scopus Author ID: 85597

Russian Federation, 194356, Россия, Санкт-Петербург, Орлово-Денисовский проспект, дом 14 строение 1; 197101, Россия, Санкт-Петербург, ул. Мира, д. 14

Doctor  of  Medicine  (MD),  Professor, Department head, leading researcher

Victor V. Rudenko

Russian Scientific Research Institute of Traumatology and Orthopedics named after R.R. Vreden, Saint Petersburg, Russia

SPIN-code: 8781-9360
Scopus Author ID: 423240

Russian Federation, 195427, Россия, Санкт-Петербург, улица Академика Байкова, 8

Ph. D. Medical Sciences, head of the neurosurgical Department


  1. (ВОЗ) Выступление Генерального директора ВОЗ на пресс-брифинге по ‎коронавирусной инфекции 2019-nCoV, 11 февраля 2020 г.‎
  2. Попова А. Ю., Ежлова Е. Б., Мельникова А. А., Башкетова Н. С., Фридман Р. К., Лялина Л. В., Смирнов В. С., Чхинджерия И. Г., Гречанинова Т. А., Агапов К. А., Арсентьева Н. А., Баженова Н. А., Бацунов О. К., Данилова Е. М., Зуева Е. В., Комкова Д. В., Кузнецова Р. Н., Любимова Н. Е., Маркова А. Н., Хамитова И. В., Ветров В. В., Миличкина А. М., Дедков В. Г., Тотолян А. А. 2020. Популяционный иммунитет к вирусу sars-cov-2 среди населения Санкт-Петербурга в активную фазу эпидемии COVID-19. (в печати).
  3. Клиническая фармакология тимогена/ под ред. проф. В.С. Смирнова. СПб, 2012.
  4. Смирнов В.С., Тотолян А.А. Врожденный иммунитет при коронавирусной инфекции. Инфекция и иммунитет. 2020; vol. 10, no 2, pp.:259-268."
  5. Смирнов В.С., Тотолян А.А. Некоторые возможности иммунотерапии при коронавирусной инфекции. Инфекция и иммунитет. 2020, Online first.
  6. Смирнов, В.С., Зарубаев В.В., Петленко С.В. Биология возбудителей и куонтрольгриппа и ОРВИ. СПб: Гиппократ, 2020
  7. Boggu P., Venkateswararao E., Manickam M. Kwak D., Kim Y., Jung S.-H.. Exploration of 2-benzylbenzimidazole scaffold as novel inhibitor of NF-κB. Bioorg. med. chem. 2016, vol. 24, no. 8, pp. 1872–1878. doi: 10.1016/j.bmc.2016.03.012.
  8. Boopathi S., Poma A.B., Kolandaivelc P. Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment J. Biomol. Struct. Dyn. 2020 : 1–10. doi: 10.1080/07391102.2020.1758788
  9. Bowie A.G., O'Neill L.A.J. Vitamin C inhibits NF-κB activation by TNF via the activation of p38 mitogen-activated protein kinase. J. Immunol. 2000, vol. 165, p. 7180–7188. doi: 10.4049/jimmunol.165.12.7180.
  10. Machhi J., Herskovitz J., Senan A.M., Dutta D., Nath B., Oleynikov M.D., Blomberg W.R., Meigs D.D., Hasan M., Patel M., Kline P., Chang R.C.-C., Chang L., Gendelman H.E., Kevadiya B.D. The Natural History, Pathobiology, and Clinical Manifestations of SARS-CoV-2 Infections. J. Neuroimmune Pharmacol. 2020, pp. 1–28. doi: 10.1007/s11481-020-09944-5
  11. Мaxim A. Shevtsov, Larisa V. Smagina, Tatiana A. Kudriavtceva, Sergey V. Petlenko, Irina V. Voronkina. / Glu-Trp-ONa or its acylated analogue (R- Glu-Trp-ONa) administration enhances the wound healing in the model of chronic skin wound in rabbits / - Drug Design, Development and Therapy. – 2015/9. - p.1717-1727
  12. Smirnov V.S., Savelyev S.A., Petlenko S.V., Redlich G., Erofeeva M.K., Lyovina A.V., Zaviyalova N.I./ Comparative efficacy and safety of preventive treatment with cytovir-3 and arbidol in children during seasonal outbreak of respiratory viral infection (an open-label randomized clinical study)/ Russian Journal of Infection and Immunity, 2019, vol.9, no.2, pp.273-278.
  13. Thevarajan I., Nguyen T.H.O., Koutsakos M., Druce J., Caly L., van de Sandt C.E., Jia X., Nicholson S., Catton M., Cowie B., Tong S.Y.C., R S.. Lewin , Katherine Kedzierska Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19 Nature Medicine 2020.

Supplementary files

There are no supplementary files to display.



Abstract - 253

PDF (Russian) - 53


Article Metrics

Metrics Loading ...




  • There are currently no refbacks.

Copyright (c) 2020 Petlenko S.V., Smirnov V.S., Rudenko V.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies